Trials / Active Not Recruiting
Active Not RecruitingNCT06704009
NT-101 Topical Ophthalmic Solution in Patients With Wet AMD
A Randomized, Open-Label, Parallel-group, Multicenter Phase 1/2 Study to Evaluate the Safety and Exploratory Efficacy of NT-101 Topical Ophthalmic Solution in Patients With Wet Age-Related Macular Degeneration (AMD)
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- NexThera Co., Ltd. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
Phase 1/2 Trial NT-101 Topical Ophthalmic Solution in Patients with Wet Age-Related Macular Degeneration (AMD)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NT-101 Low Dose | Low concentration of NT-101 (0.05 mM) |
| DRUG | NT-101 High Dose | High concentration of NT-101 (0.2 mM) |
Timeline
- Start date
- 2025-03-11
- Primary completion
- 2025-12-15
- Completion
- 2026-05-01
- First posted
- 2024-11-25
- Last updated
- 2026-04-08
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06704009. Inclusion in this directory is not an endorsement.